J&J to pay $2 billion for cancer drug developer Ambrx Biopharma

Ambrx specializes in targeted chemotherapy treatments — one of the hottest areas of cancer drug development. 

January 9, 2024 Check out STAT+

Sponsored By

AP/Richard Drew STAT+ | The ADC hot streak continues: J&J to buy cancer drug developer Ambrx Biopharma Ambrx develops antibody-drug conjugates, treatments that link powerful chemotherapies to homing devices meant to deliver them to tumors. By Andrew Joseph STAT+ | Insitro, biotech AI's quiet unicorn, unveils efforts in ALS, liver disease, and cancer at JPM Biotech founded by Daphne Koller makes news ahead of JPM conference with new papers on drugs for cancer, ALS, liver disease; poaches new CMO from Pfizer. By Matthew Herper STAT+ | Merck to acquire Harpoon Therapeutics for $680 million The bolt-on deal comes as Merck's top brass searches for ways to bolster the company's revenue after it loses exclusivity on Keytruda. By Jason Mast

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Cancer Briefing? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser